AB-101, an Off-the-Shelf NK Cell Therapy Administered in an Outpatient Community Rheumatology Practice, Is More Cost-Effective Than CAR-T Treatments for Rheumatologic Diseases

Key Points

• AB-101 NK cell therapy demonstrates higher cost-effectiveness compared to CAR-T treatments, especially in outpatient settings.
• Cost savings were significant, reducing financial burdens for patients needing rheumatologic disease therapy.
• The analysis focuses on outpatient community rheumatology practices, indicating a shift in treatment approaches.
• Findings suggest potential for broader use of NK cell therapy, enhancing patient access to care in rheumatologic disorders.